

RECEIVED
APR 19 2005
FAX

FAX TRANSMISSION**DATE:** April 19, 2005**PTO IDENTIFIER:** Application Number 10/506592
Patent Number**Inventor:** Andrew David Morley**MESSAGE TO:** Office of Initial Patent Examination**FAX NUMBER:** (703) 872-9306**FROM:** ROPES & GRAY LLP
David P. Halstead, Ph.D.**PHONE:** (617) 951-7615**Attorney Dkt. #:** ASZD-P01-659**PAGES (Including Cover Sheet):** 10**CONTENTS:** First Preliminary Amendment (9 pages)
This Facsimile Cover Sheet (1 page)

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (617) 951-7615 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

ROPES & GRAY LLP
One International Place, Boston, Massachusetts 02110-2624
Telephone: (617) 951-7000 **Facsimile:** (617) 951-7050

I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, facsimile no. (703) 872-9306, on the date shown below.

Dated: April 19, 2005

Signature:

Mary Jane DiPalma
(Mary Jane DiPalma)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Andrew David Morley

Serial No: 10/506592

Filed: September 3, 2004

For: INDOLE-AMIDE DERIVATIVES
AND THEIR USE AS GLYCOGEN
PHOSPHORYLASE INHIBITORS

Attorney Docket No.: ASZD-P01-659

Art Unit: 1615

Examiner: Not Yet Assigned

Confirmation No.: 2926

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FIRST PRELIMINARY AMENDMENT

Sir:

Prior to examination on the merits, please amend the above-identified U.S. patent application as follows:

Amendments to the specification begin on page 2 of this paper.

Amendments to the claims begin on page 4 of this paper.

Remark begin on page 9 of this paper.